NEW YORK (GenomeWeb) — Affymetrix and Ariosa Diagnostics today announced that they have signed a multi-year agreement under which Affymetrix will supply arrays and instruments for use in Ariosa's Harmony non-invasive prenatal test.

The deal "opens up the possibility to further broaden access to the Harmony test via a kit decentralization strategy," Ariosa CEO Ken Song said in a statement. Under such a strategy other laboratories would be able to run the array-based test in house.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.